RxDoctor Payments Data

Maria Pilar Elisa Dayaw, MD

Neurology · Hopedale, MANPI 1831283118

Payments from drug & device makers

$311,317in general payments, 2019–2025

Across 2,010 payments — averaging $154.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EMD Serono, Inc.$82K
  • Biogen$71K
  • Eisai Inc.$33K
  • Sanofi$32K
  • ANI Pharmaceuticals, Inc.$20K
  • E.r. Squibb & Sons, L.L.C.$19K
  • plus $53K from 54 others

What the payments were for

  • Consulting fees$34,77811%
  • Speaking & faculty fees$204,46466%
  • Travel & lodging$27,3359%
  • Food & beverage$44,09614%
  • Education$6430%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
EMD Serono, Inc.156$82,330
Biogen162$71,369
Eisai Inc.110$32,778
Sanofi83$32,393
ANI Pharmaceuticals, Inc.69$20,180
E.r. Squibb & Sons, L.L.C.28$19,450
Bristol Myers Squibb77$14,270
Genentech USA, Inc.30$5,645
Novartis129$4,539
TG Therapeutics, Inc.17$4,227
AbbVie(2 entities)156$3,026
Lundbeck LLC113$2,644
Teva Pharmaceuticals USA, Inc.77$1,296
SK Life Science, Inc.46$1,220
MDD US Operations, LLC44$1,121
Pfizer64$1,090
UCB, Inc.59$1,044
AstraZeneca(2 entities)37$935
CSL Behring38$902
Amneal Pharmaceuticals LLC45$898
Lilly USA, LLC46$789
Mallinckrodt Hospital Products Inc.22$699
Merz Pharmaceuticals, LLC20$694
Johnson & Johnson18$509
Mallinckrodt Enterprises LLC23$501
Sunovion Pharmaceuticals Inc.31$493
Amgen(2 entities)18$445
Supernus Pharmaceuticals, Inc.23$439
Alnylam Pharmaceuticals Inc.10$411
Acorda Therapeutics, Inc32$408
Otsuka America Pharmaceutical, Inc.14$356
Biohaven Pharmaceuticals, Inc.17$313
Neurocrine Biosciences, Inc.15$298
Harmony Biosciences LLC5$285
Biohaven Pharmaceutical Holding Company Ltd.19$251
Vanda Pharmaceuticals Inc.12$222
Axsome Therapeutics, Inc.13$219
Grifols USA, LLC12$212
Acadia Pharmaceuticals Inc11$212
Neurelis, Inc.10$198
Idorsia Pharmaceuticals US Inc4$187
Impel Pharmaceuticals Inc.13$182
Argenx US, Inc.9$181
Tanabe Pharma America, Inc.7$147
Takeda Pharmaceuticals U.S.A., Inc.6$123
GE HealthCare7$116
Kyowa Kirin, Inc.5$107
Upsher-smith Laboratories LLC4$97
Inspire Medical Systems, Inc.4$78
Life Molecular Imaging Ltd4$78
Avanir Pharmaceuticals, Inc.4$76
Arbor Pharmaceuticals, Inc.3$72
Catalyst Pharmaceuticals, Inc.3$69
Almatica Pharma LLC2$53
Scilex Pharmaceuticals Inc.2$50
Insightec,inc2$42
Avion Pharmaceuticals2$36
Xeris Pharmaceuticals, Inc.2$34
Livanova USA, Inc.2$33
Greenwich Biosciences, Inc.1$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$311,317 in reported general payments places this provider in the 85th percentile of 761 neurology providers in Massachusetts.

See all neurology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$145,140
Medicare patients
261
Services billed
1,644

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab73$694,134
Teriflunomide139$346,817
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5064$224,945
TecfideraDimethyl Fumarate19$170,449
Plegridy PenPeginterferon Beta-1a16$130,133
Dimethyl Fumarate42$87,943
Nurtec OdtRimegepant Sulfate27$43,570
Rivastigmine80$23,246
Aimovig AutoinjectorErenumab-Aooe25$22,407
Emgality PenGalcanezumab-Gnlm29$21,309
Dalfampridine ErDalfampridine37$15,121
Memantine Hcl209$10,513
NamzaricMemantine Hcl/Donepezil Hcl15$10,003
Topiramate ErTopiramate25$8,117
Gabapentin302$3,912

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$123$224,94564 claims
BiogenTecfidera$71,369$170,44919 claims
PfizerNurtec Odt$1,090$43,57027 claims
AbbVieNamzaric$3,026$10,00315 claims
Upsher-smith Laboratories LLCTopiramate$97$92264 claims
Almatica Pharma LLCSertraline Hcl$53$52052 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 761 neurology providers in Massachusetts.

Other neurology in Hopedale

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →